STEP (striatal-enriched phosphatase) is a non-receptor tyrosine phosphatase that is specifically expressed in the neurons of the central nervous system. STEP regulates the activity of several effector molecules involved in synaptic plasticity and neuronal cell survival, including MAPKs (mitogen-activated protein kinases), Src family kinases and NMDA (N-methyl-D-aspartic acid) receptors. The critical role of STEP in regulating these effectors requires that its activity be tightly regulated. Previous studies have demonstrated that the activity of STEP is regulated through reversible phosphorylation of a serine residue within the KIM (kinase-interacting motif), by cAMP-dependent PKA (protein kinase A). In the present paper we show that STEP is endogenously phosphorylated at two additional sites located within the KISs (kinase-specificity sequences). The basal activity of ERK (extracellular-signal-regulated kinase) and p38 MAPKs plays an important role in the phosphorylation of these two sites. Dephosphorylation of these two sites leads to polyubiquitination and proteolytic degradation of STEP. Conversely, the proteasome inhibitors MG-132 and epoxomicin can stabilize STEP. The active form of STEP is more susceptible to degradation than the inactive form. Taken together the results of the present paper establish that ubiquitin-dependent proteolysis could be a novel mechanism for irreversibly terminating the activity of STEP.
INTRODUCTION
PTPs (protein tyrosine phosphatases) are a large family of structurally diverse proteins that, together with tyrosine kinases, regulate the tyrosine phosphorylation state of many important signalling molecules. It is now apparent that PTPs exhibit exquisite substrate specificity and are critical regulators of a wide array of cellular signalling pathways [1, 2] . However, an important area in the field that remains to be investigated is the characterization of mechanisms by which the activity of PTPs themselves may be regulated.
STEP (striatal-enriched phosphatase, also known as PTPN5) is an intracellular PTP that is expressed exclusively in the central nervous system and whose specific targets and functions are beginning to emerge. STEP is expressed preferentially in neurons of the basal ganglia, hippocampus, cortex and related structures [3, 4] . The STEP family of PTPases includes both membraneassociated (STEP 61 ) and cytosolic (STEP 46 ) variants that are formed by alternative splicing of a single gene [5] . STEP 61 differs from STEP 46 by the presence of an additional 172 amino acids at its N-terminus [6] . STEP, along with two other PTPs, PTPRR (PTP receptor type R, also known as PTP-SL) and PTPN7 (PTP non-receptor type 7, also known as HePTP) belongs to a family of PTPs that contains a highly conserved 16-amino-acid substrate-binding domain termed the KIM (kinase-interacting motif) domain [7] . A regulatory serine residue lies in the middle of the KIM domain (Ser 49 in STEP 46 and Ser 221 in STEP 61 ) and dephosphorylation of this residue renders STEP active in terms of its ability to bind to its substrates. Phosphorylation of Ser 49 and Ser 221 is mediated by dopamine/D1 receptor-dependent activation of the cAMP/PKA (protein kinase A) pathway [8] , whereas dephosphorylation is mediated by glutamate/NMDA (Nmethyl-D-aspartic acid) receptor-induced activation of the Ca 2 + -dependent phosphatase calcineurin [9] .
In its active form STEP can modulate synaptic plasticity by regulating the activity of ERK (extracellular-signal-regulated kinase) 1/2, a key protein involved in memory formation [10, 11] . Active STEP can also modulate NMDA receptor-dependent longterm potentiation by interfering with NMDA receptor trafficking to the synaptic membrane, possibly through regulation of the upstream kinase Fyn [12] and tyrosine dephosphorylation of NR2B (NMDA receptor 2B)-NMDA receptor subunits [13] . Several studies have also indicated the role of active STEP in neuroprotection through its regulation of p38 MAPK (mitogenactivated protein kinase) [14, 15] .
Although reversible phosphorylation of Ser 49 /Ser 221 within the KIM domain appears to play an important regulatory function, additional mechanisms may also exist for stricter control of STEP activity. It has been reported that there is a second conserved domain C-terminal to the KIM domain present in STEP, PTPRR and PTPN7. This domain has been termed the KIS (kinasespecificity sequence) domain [16] . The aim of the present study was to investigate the role of the KIS domain in regulating the function of STEP. The results show that in intact cells STEP is phosphorylated at two specific sites within the KIS domain. Dephosphorylation of these two sites leads to degradation of Abbreviations used: AD, Alzheimer's disease; Cdk5, cyclin-dependent kinase 5; DMEM, Dulbeco's modified Eagle's medium; ERK, extracellular-signalregulated kinase; HRP, horseradish peroxidase; KIM, kinase-interacting motif; KIS, kinase-specificity sequence; MAPK, mitogen-activated protein kinase; N2A, neuroblastoma 2A; NMDA, N-methyl-D-aspartic acid; NR2B, NMDA receptor 2B; PKA, protein kinase A; pNPP, p-nitrophenyl phosphate; PSD-95, post-synaptic density-95; PTP, protein tyrosine phosphatase; PTPN7, PTP non-receptor type 7; PTPRR, PTP receptor type R; STEP, striatal-enriched phosphatase; WT, wild-type. 1 To whom correspondence should be addressed (email spaul@salud.unm.edu).
STEP and the active form of STEP is specifically targeted for degradation by ubiquitination. 
EXPERIMENTAL

Cell culture and stimulation
HeLa, Cos-7 and N2A cells were grown in DMEM (Dulbecco's modified Eagle's medium) containing 1× antibiotics/antimycotic and 10 % foetal bovine serum, at 37
• C in a humidified atmosphere consisting of 5 % CO 2 and 95 % air. Cells were transiently transfected with 2 μg of DNA using Lipofectamine TM 2000 (Invitrogen). After 18 h the cells were treated with or without MG-132 (25 and 50 μM) and epoxomicin (2.5, 5 and 10 μM) for 6 and 9 h at 37
• C. Cells were either processed for immunoprecipitation or lysed in buffer containing 62.5 mM Tris/HCl (pH 6.8), 2 % SDS, 10 % glycerol and 5 % 2-mercaptoethanol. Immune complexes and lysates were then subjected to SDS/PAGE (8 % gel) and immunoblotting analysis. In some experiments PD98059 (20 μM) and SB203580 (20 μM) were added 6 h after transfection. Cells were harvested after a further 6 h and processed for SDS/PAGE (8 % gel) and immunoblotting analysis.
Immunoprecipitation
Cells were lysed in a buffer containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 0.1 % Nonidet P40 and protease inhibitor cocktail (Boehringer). Lysates were centrifuged for 10 min at 18 000 g at 4
• C to remove insoluble material, and then pre-cleared with Protein GSepharose for 1 h. For immunoprecipitation of STEP or ubiquitin, samples were incubated overnight with anti-V5 or anti-ubiquitin antibody. The immune complexes were incubated with 30 μl of Protein G-Sepharose for 2 h at 4
• C. Beads were collected by centrifugation at 100 g for 2 min at 4
• C and washed five times with lysis buffer. Proteins were eluted using SDS sample buffer and processed for SDS/PAGE and immunoblotting analysis with antibodies, as described in the individual experiments.
Immunoblotting
Equal amount of protein lysates, as estimated using a bicinchoninic acid protein assay kit (Pierce Biotechnology), were resolved by SDS/PAGE (8 % gel) and transferred on to PVDF membranes. The membranes were blocked for 1 h at room temperature (25
• C) with 5 % non-fat dried milk and then incubated for 1 h at room temperature or at 4
• C overnight with the appropriate primary antibody. HRP coupled to anti-rabbit or anti-mouse IgG raised in goat were used as secondary antibodies. Immune complexes were detected on X-ray film after treatment with West Pico super signal chemiluminescence reagent (Pierce Biotechnology).
Phosphatase activity assay
HeLa cells were transfected with V5-tagged STEP 46 S49A or one of its mutants. After 24 h cells were lysed in a buffer containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl and 1 % Triton X-100. Half of the lysate was processed for immunoblot analysis of immunoprecipitated STEP and the remaining half was used for the phosphatase assay. STEP 46 was immunoprecipitated using an anti-V5 antibody. The immune complexes bound to Protein G beads were then washed three times in a buffer containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.1 % Triton X-100 and then once in a buffer containing 30 mM Hepes (pH 7.0) and 120 mM NaCl. For the pNPP (p-nitrophenyl phosphate) assay, the beads were incubated in 100 μl of reaction mixture containing 30 mM Hepes (pH 6), 120 mM NaCl and 10 mM pNPP for 30 min at 30
• C. The reactions were terminated by the addition of 900 μl of 0.2 M NaOH. Phosphatase activity of the STEP 46 mutants was measured by colorimetric quantification of the formation of p-nitrophenolate at 410 nm using a spectrophotometer. The values obtained were normalized for the amount of STEP immunoprecipitated [17] .
RNA isolation and cDNA synthesis
Total RNA was isolated using RNeasy kits (Qiagen) from HeLa cells transiently transfected for 24 h with either STEP 46 S49A or its mutant STEP 46 S49A/T59A/S72A. The quality of the RNA was analysed by electrophoresis on 1 % agarose gels. Each RNA (2 μg) was used for cDNA synthesis with a Superscript III cDNA synthesis kit (Invitrogen), using oligo(dT). The following primers were used for subsequent PCR-based amplification (16, 20, 25 and 30 cycles) of STEP 46 (forward, 5 -ATGGAGGAGAAGGTAGAGGATGAC-3 and reverse 5 -CTCTGAGGACTGGAGGGTCAGCTG-3 ). Amplification (16, 20, 25 and 30 cycles) of β-actin (forward, 5 -GCTCGTCGTCGACAACGGCT-3 and reverse, 5 -CAAACATGATCTGGGTCATCTTCTC-3 ) was performed as a control to show that equal amounts of starting total RNA were present in each sample. The PCR products were analysed by agarose gel electrophoresis.
Pulse-chase experiments
HeLa cells expressing STEP 46 S49A or STEP 46 S49A/T59A/S72A were washed twice with warm PBS and then incubated for 30 min at 37
• C in methionine/cysteine-free DMEM supplemented with 5 % dialysed foetal bovine serum. Cells were then incubated with [ 35 S] Protein Labeling Mix (0.1 mCi per plate) in fresh methionine/cysteine-free DMEM supplemented with 5 % dialysed foetal bovine serum for 45 min. The radiolabel was then removed by washing the cells twice with PBS followed by incubation at 37
• C in warm DMEM supplemented with 10 % foetal bovine serum and 2 mM each of cysteine and methionine for the specified time periods. The medium was then removed, and the cells were rinsed twice with ice-cold PBS. Cells were then lysed in a buffer containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 0.1% Nonidet P40 and protease inhibitor cocktail (Boehringer) and then processed for immunoprecipitation.
P-labelling of cells
HeLa cells expressing WT (wild-type) STEP 46 or one of its mutants were grown for 24 h in the presence of DMEM containing 1× antibiotics/antimycotic and 10 % foetal bovine serum. The cells were then grown in phosphate-free DMEM containing 0.5 % serum for 18 h and then incubated with [ 32 P]sodium phosphate (0.3 mCi per plate) for an additional 6 h in the same medium. The labelling buffer was then removed, and the cells were rinsed twice with ice-cold PBS (pH 7.4). Cells were then lysed and processed for immunoprecipitation as described above.
Statistical analysis
Densitometric analysis of the 35 S-and 32 P-labelled STEP bands in the autoradiogram as well as the levels of STEP and ubiquitin proteins detected in immunoblots was performed using Image J software (http://rsbweb.nih.gov/ij/). Statistical comparison was done using one-way ANOVA with post hoc Bonferroni's correction, and differences were considered significant at P < 0.05.
RESULTS
STEP is phosphorylated endogenously at SP/TP sites in the KIS domain
STEP 61 and STEP 46 both include the KIM and KIS domains and the phosphatase motif (PTP domain) ( Figure 1 ). Both STEP 61 and STEP 46 are phosphorylated endogenously at a consensus PKA phosphorylation site within the KIM domain (Ser 221 in STEP 61 and Ser 49 in STEP 46 ) [8] . Additionally, a serine and a threonine residue (Thr 231 /Thr 59 and Ser 244 /Ser 72 ) are present in the KIS domain within the consensus sequences of proline-directed kinases (SP/TP sites; Figure 1 ). Initial experiments explored the possibility of endogenous phosphorylation of these two sites in HeLa cells. Cells were transfected with either V5-tagged wild-type STEP 46 (STEP 46 WT) or its mutant that cannot be phosphorylated endogenously at the KIM domain serine residue (V5-tagged STEP 46 S49A) and then labelled with [ 32 P]P i for 6 h. STEP was then immunoprecipitated using an anti-V5 antibody, resolved by SDS/PAGE, transferred on to PVDF membrane and processed for autoradiography. A phosphoprotein of ∼ 50 kDa was detected by autoradiography in cell lysates transfected with STEP 46 WT ( Figure 2A , top panel). Immunoblot analysis identified the protein as STEP 46 ( Figure 2A , middle panel). This is consistent with earlier findings that STEP is endogenously phosphorylated at the PKA site within the KIM domain [8] . Consistent with this idea, mutation of this site (STEP 46 S49A) reduced greatly, but did not abolish, phosphorylation of the mutant form ( Figure 2A ). Thus a phosphoprotein of similar molecular mass was observed in cell lysates transfected with STEP 46 S49A, although the level was low and the band position was slightly lower than that observed with STEP 46 WT (Figure 2A ). Such a downward shift in mobility has been reported in previous studies of STEP 46 following dephosphorylation or mutation of the PKA site [9, 13, 14] . Phosphorylation of mutant STEP 46 (STEP 46 S49A) implies, that in addition to the PKA site within the KIM domain, STEP 46 must be endogenously phosphorylated at other sites.
To determine whether the SP/TP sites in the KIS domain (Thr 59 and Ser 72 ) are endogenously phosphorylated, HeLa cells were transfected with either V5-tagged STEP 46 S49A or one of its mutants (S49A/T59A, S49A/S72A or S49A/T59A/S72A). Cells were labelled with [ 32 P]P i and then processed for immunoprecipitation of STEP and analysis by autoradiography and immunoblotting as described above. Figure 2 were converted into an alanine residue (STEP 46 S49A/T59A/S72A), to mimic the nonphosphorylatable form, no specific band was observed either in the autoradiogram ( Figure 2B , top panel) or in the immunoblotting ( Figure 2B , middle panel), suggesting that mutation of both Thr 59 and Ser 72 may lead to loss of expression of STEP. To further test whether phosphorylation of both of these sites is essential for maintaining STEP expression, additional mutants were constructed where one site in the KIS domain was converted into glutamic acid to mimic the phosphorylated form, and the other site was converted into alanine to make it non-phosphorylatable (S49A/T59E/S72A and S49A/T59A/S72E). These results were compared with mutants where both sites were converted into
Figure 2 Endogenous phosphorylation of STEP at SP/TP sites in the KIS domain
HeLa cells were transiently transfected with V5-tagged STEP 46 (WT) or its mutant STEP 46 S49A that cannot be phosphorylated at the serine residue in the KIM domain (A), V5-tagged STEP 46 S49A or one of its mutants where Thr 59 and/or Ser 72 in the KIS domain were converted into an alanine residue (S49A/T59A, S49A/S72A or S49A/T59A/S72A) to render them non-phosphorylatable (B) and V5-tagged STEP 46 S49A or one of its mutants where Thr 59 and/or Ser 72 in the KIS domain were converted to a glutamic acid residue (T59E/S72A, T59A/S72E or T59E/S72E) to mimic the phosphorylated form (C). The cells were labelled 24 h after transfection with [ 32 P]P i . STEP was immunoprecipitated from cell lysates using an anti-V5 antibody, resolved on SDS/PAGE, transferred on to PVDF membrane and processed for autoradiography (top panels) and immunoblot analysis (middle panels). The line on the right-hand side of each representative autoradiograph (top panel) indicates the position of the phosphorylated protein band corresponding to STEP 46 . The molecular mass standards are indicated in kDa on the left-hand side of the upper panel. The phosphorylated bands were identified as STEP by probing the membrane with an anti-STEP antibody (middle panels). Immunoprecipitation (IP) with Protein-G-Sepharose alone was used as a control. Quantification of phosphorylated STEP 46 a glutamic acid residue (S49A/T59E/S72E) to mimic the phosphorylated form. Figure 2 (C) shows that expression of both the phosphorylatable (STEP 46 S49A) and the phosphomimicking forms (S49A/T59E/S72A, S49A/T59A/S72E and S49A/T59E/S72E) were stable ( Figure 2C , middle panel), even though only STEP 46 S49A could be phosphorylated ( Figure 2C , top panel). Taken together, these results indicate that both Thr 59 and Ser 72 are endogenously phosphorylated in intact cells and that phosphorylation of at least one of these sites is necessary for maintaining expression of STEP 46 that is dephosphorylated at the serine residue within the KIM domain.
Dephosphorylation of the SP/TP sites in the KIS domain does not affect the association of STEP with its substrate or phosphatase activity
Dephosphorylation of STEP 46 at the serine residue within the KIM domain (Ser 49 ) allows STEP to bind to its substrates for subsequent dephosphorylation [9] . To examine the consequence of phosphorylation/dephosphorylation of the KIS domain sites on the association of STEP with its downstream target ERK2, we generated a dominant-negative variant of STEP (STEP 46 S49A/C300S) where the KIM domain serine residue was converted into an alanine (S49A) so that it can constitutively bind its substrate(s) and the regulatory cysteine residue in the phosphatase domain was converted into a serine (C300S) so that it is enzymatically inactive (phosphatase-dead form). HeLa cells were co-transfected with Myc-ERK2 and V5-STEP 46 S49A/C300S or one of its mutants (S49A/T59E/S72E/C300S, S49E/T59E/S72E/C300S, S49E/T59A/S72A/C300S, S49A/ T59A/C300S or S49A/S72A/C300S). STEP was immunoprecipitated using the anti-V5 antibody and co-immunoprecipitation of ERK2 was determined by immunoblotting with an anti-ERK2 antibody. The results indicate that in intact cells the STEP mutants, where the KIM domain serine residue was mutated to an alanine, were able to interact with ERK2. In these mutants conversion of the KIS domain sites into either an alanine (non-phosphorylatable form) or glutamic acid (phosphomimicking form) residue did not affect the interaction of STEP with ERK2 ( Figure 3A ). However conversion of the KIM domain regulatory serine residue into glutamic acid (phospho-mimicking form) inhibited the interaction of STEP with ERK2, irrespective of the phosphorylation status of the KIS domain sites ( Figure 3A) . To determine whether mutation of the KIS domain sites either to an alanine or glutamic acid residue has any effect on the phosphatase activity of STEP, HeLa cells were transfected with V5-STEP 46 S49A or one of its mutants (S49A/T59E/S72E, S49E/T59E/S72E or S49E/T59A/S72A). Tyrosine phosphatase activity of immunoprecipitated STEP was measured using pNPP as a substrate and the values were normalized for the amount of STEP immunoprecipitated. The results show that there was no change in phosphatase activity of STEP 46 when the phosphorylation sites in the KIS domain was converted into either glutamic acid or alanine ( Figure 3B ). Taken together these findings suggest that phosphorylation/dephosphorylation of the SP/TP sites in the KIS domain does not affect the intrinsic catalytic activity or the interaction of active STEP with its downstream target. 
Dephosphorylation of active STEP at the SP/TP sites in the KIS domain leads to its loss of expression
To determine whether the active form of STEP 46 is more susceptible to destabilization, either STEP 46 WT or one of its mutants (S49A, T59A/S72A or S49A/T59A/S72A) was transfected into both HeLa and Cos-7 cells and expression levels were analysed by immunoblot analysis of total cell lysates. Figure 4 (A) shows that expression levels of STEP 46 WT (inactive form), STEP 46 S49A (active form) and STEP 46 T59A/S72A (inactive form dephosphorylated at the two phosphorylation sites in the KIS domain) remained unaltered. However, there was a significant loss in expression of the STEP 46 S49A/T59A/S72A, the active form of STEP dephosphorylated at the two phosphorylation sites within the KIS domain ( Figure 4A ). Additional evidence that active STEP is more susceptible to destabilization was obtained from mutants that mimic the inactive form of STEP and are dephosphorylated at the two phosphorylation sites in the KIS domain (STEP 46 S49E/T59A/S72A). Immunoblot analysis showed that there was no significant loss in expression of the inactive mutant of STEP 46 , even in the complete absence of KIS domain phosphorylation ( Figure 4B ). Further analysis was also carried out with the STEP 61 WT variant (inactive form) and its corresponding mutants S221A (active form) and S221A/T231A/S244A (active form dephosphorylated at the two phosphorylation sites within the KIS domain). As shown in Figure 4 (C) the expression profile of STEP 61 WT and STEP 61 S221A remained unaltered in both HeLa and Cos-7 cells. However, a significant loss in expression of STEP 61 S221A/T231A/S244A was observed in both of the cell types ( Figure 4C ), which is consistent with our findings in STEP 46 .
To evaluate whether the loss of expression of active STEP following mutation of the sites in the KIS domain may be attributed to reduced transcription, HeLa cells were transiently transfected with STEP 46 S49A or STEP 46 S49A/T59A/S72A. Total RNA isolated from the cell lysates were used for cDNA synthesis and subsequent PCR amplification (16, 20, 25 and 30 cycles) with primers against STEP 46 as described in the Experimental section. Analysis of PCR products by agarose gel electrophoresis showed a single band in the gel demonstrating that the amplification was RNA specific. Additionally there were no differences in the amounts of PCR products between STEP 46 S49A and STEP 46 S49A/T59A/S72A in any of the cycles tested (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/440/bj4400115add.htm). Amplification of the PCR product using primers specific for β-actin confirmed that equal amounts of cDNA were amplified in each sample. Taken together the findings shown in Figure 4 and Supplementary Figure S1 demonstrate that the loss of expression of active STEP observed in both HeLa and Cos-7 cells (Figure 4) was not regulated by transcription, but rather the active form of STEP appears susceptible to destabilization following dephosphorylation of the SP/TP sites within the KIS domain.
SP/TP sites are putative MAPK target sites and two members of this family, ERK and p38 MAPK, are known to interact with STEP [9, 14] . To examine whether ERK-and p38 MAPKdependent phosphorylation of the two SP/TP sites in the KIS domain leads to stabilization of STEP, several additional mutants were constructed using STEP 46 S49A/C300S, the dominantnegative form that can bind constitutively to its substrates, as the template. In the first two mutants one of the phosphorylation sites in the KIS domain was converted into an alanine residue to render it non-phosphorylatable, whereas the other remained accessible to phosphorylation by endogenous kinases (STEP 46 S49A/T59A/C300S and STEP 46 S49A/S72A/C300S). In the third mutant both the KIS domain sites were converted into a glutamic acid residue to mimic the phosphorylatable form (STEP 46 S49A/T59E/S72E/C300S). HeLa cells expressing these mutants were treated with pharmacological inhibitors of both ERK (PD98059, 20 μM) and p38 (SB203580, 20 μM) MAPKs [18, 19] . Immunoblot analysis of total lysates showed a significant decrease in the expression of STEP mutants, in the presence of MAPK inhibitors, where either Thr 59 or Ser 72 was accessible to phosphorylation ( Figures 5A and 5B, top panel) . However the expression of the phospho-mimicking form remained unaltered in the absence or presence of MAPK inhibitors ( Figure 5C , upper panel). Thus it is probable that the basal activity of either ERK or p38 MAPK is essential for phosphorylation of Thr 59 and Ser 72 to maintain the stability of STEP. Inhibition of ERK or p38 MAPKs individually did not significantly affect the level of expression of the STEP mutants (results not shown) indicating that the loss of activity of one of the MAPKs may be compensated by the other.
Dephosphorylation of the SP/TP sites in the KIS domain results in ubiquitin-mediated proteasomal degradation of active STEP
We next determined the time course of changes in the expression of active STEP and its mutant form that cannot be phosphorylated endogenously at the SP/TP sites within the KIS domain. HeLa cells were transiently transfected with V5-tagged STEP 46 S49A or STEP 46 S49A/T59A/S72A. At specific time points after transfection (6, 12, 18 and 24 h) cells were harvested, lysed and processed for immunoblot analysis. As shown in Figure 6 (A) HeLa and Cos-7 cells were transiently transfected with V5-tagged STEP 46 (WT) or one of its mutants (S49A, T59A/S72A or S49A/T59A/S72A) (A), V5-tagged STEP 46 (WT), STEP 46 S49A or one of its mutants (S49A, S49A/T59A/S72A or S49E/T59A/S72A) (B) and V5-tagged STEP 61 (WT) or one of its mutants (S221A or S221A/T231A/S244A) (C). Expression of the STEP variants was analysed by probing total cell lysates with an anti-V5 antibody. Equal protein loading was confirmed by re-probing the blots using a polyclonal antibody against endogenously expressed β-tubulin. 35 S]methionine/cysteine protein labelling mix for 45 min (pulse) and the labelled products were then followed (chase) by replacing the medium with a non-radioactive medium containing an excess of unlabelled methionine/cysteine. The degradation pattern of 35 S-labelled STEP 46 S49A and STEP 46 S49A/T59A/S72A was monitored by immunoprecipitating them from cell lysates obtained at various time points during the chase. Analysis of the immunoprecipitates by SDS/PAGE and autoradiography showed a significant increase in the rate of degradation of active STEP 46 S49A/T59A/S72A ( Figures 6B and 6C) , where the phosphorylation sites within the KIS domain were mutated to an alanine residue (nonphosphorylatable form).
To clarify the mechanism(s) by which the active form of STEP is degraded following dephosphorylation of Thr 59 and Ser 72 in the KIS domain we tested the effects of two well-established proteasome inhibitors MG-132 and epoxomicin [20, 21] . HeLa and Cos-7 cells were transiently transfected with V5-tagged STEP 46 S49A/T59A/S72A and then treated with one of the inhibitors (MG-132, 25-50 μM; epoxomicin, 2.5-10 μM) for 6 or 9 h. Figure 7 shows that both inhibitors effectively prevented STEP degradation. Exposure to 25 μM MG-132 for 6 or 9 h was sufficient to enhance the expression of STEP 46 S49A/T59A/S72A in HeLa cells (∼3-fold increase, Figure 7A ). In Cos-7 cells the level of STEP expression also increased (∼3-3.5 fold) following 9 h treatment with 25 μM MG-132 ( Figure 7B ). Epoxomicin exerted similar effects at a minimum concentration of 2.5 μM (9 h treatment), in both HeLa and Cos-7 cells (Figures 7C and 7D ). These findings are consistent with a primary role for proteasomal degradation of active STEP.
Ubiquitination is an important first step in proteasomal degradation and it is well established that when a substrate protein is marked with multiple ubiquitin peptides (generally four or more), this complex can be recognized by proteasomes resulting in degradation [22] . We next tested whether STEP is ubiquitinated prior to degradation. HeLa cells were transfected with V5-tagged STEP 46 S49A/T59A/S72A that is susceptible to degradation and treated with MG-132 or epoxomicin. STEP was immunoprecipitated and immune complexes were processed for immunoblotting with an anti-ubiquitin antibody. In the absence of MG-132 or epoxomicin, most of the STEP 46 S49A/T59A/S72A was degraded and accumulation of ubiquitinated STEP 46 S49A/T59A/S72A was minimal ( Figures 8A, bottom panel and  8C) . In the presence of MG-132 or epoxomicin the level of expression of STEP 46 S49A/T59A/S72A increased significantly as compared with the untreated control (Figures 8A, bottom panel and 8C) and formed a stable complex with ubiquitin as evident from co-immunoprecipitation of ubiquitin along with STEP ( Figures 8A, top panel and 8B) . In a reverse set of experiments ubiquitin was immunoprecipitated and coimmunoprecipitation of STEP with ubiquitin was analysed using an anti-V5 antibody. A considerable increase in coimmunoprecipitation of STEP 46 S49A/T59A/S72A along with ubiquitin was observed in cells treated with MG-132 or epoxomicin (results not shown), consistent with our hypothesis that ubiquitin-mediated proteasomal degradation plays a critical role in the regulation of the level of STEP. Since STEP is predominantly expressed in neurons, in a final set of experiments we examined whether the mechanisms described above for degradation of active STEP also apply following expression in the more neuron-like N2A cells that do endogenously express STEP. Cells were transfected with STEP 46 WT or its mutants (S49A, T59A/S72A or S49A/T59A/S72A) and cell lysates were processed for immunoblot analysis with the anti-V5 antibody. Consistent with our observation in HeLa and Cos-7 cells, a loss in stability/expression was only observed with the STEP 46 S49A/T59A/S72A mutant in N2A cells ( Figure 9A ). Furthermore, treatment of cells expressing V5-tagged STEP 46 S49A/T59A/S72A with MG-132 followed by immunoprecipitation of STEP and immunoblot analysis with an anti-ubiquitin antibody imply a similar dependence on ubiquitinmediated proteasomal degradation. Accordingly, a significant increase in the STEP 46 S49A/T59A/S72A level ( Figure 9B ) as well as STEP 46 S49A/T59A/S72A-ubiquitin complex formation (∼2.5-fold) was seen in the presence of MG-132 ( Figure 9C ).
DISCUSSION
The present study highlights the role of the KIS domain in the regulation of the level of active STEP. We identified two SP/TP sites in the KIS domain whose phosphorylation is mediated primarily through the basal activity of ERK and p38 MAPKs. Dephosphorylation of these two sites selectively results in ubiquitinmediated degradation of the active form of STEP. The effects of proteasome inhibitors also strongly implicate a role of the proteasomal machinery in degradation of active STEP. Previous studies have demonstrated that a major switch in the ability of STEP to bind to its substrate(s) involves reversible phosphorylation and dephosphorylation of a serine residue within the KIM domain [8, 9] . The specific proteolysis of the active form of STEP, as demonstrated in the present study, reveals a previously unidentified cellular mechanism for irreversibly attenuating STEP activity.
Our findings indicate that the serine residue within the KIM domain (Ser 49 ) is not the only site involved in phosphorylation of STEP in intact cells. Threonine and serine residues (Thr 59 and Ser 72 ) present within the consensus sequences of proline-directed kinases in the KIS domain are also endogenously phosphorylated in STEP. The fact that mutation of S72A in the active form of STEP (STEP 46 S49A) results in a ∼55 % reduction in active STEP phosphorylation, whereas mutation of T59A results in a ∼25 % reduction may suggest that Ser 72 is a major phosphorylation site in addition to Ser 49 . Alternatively, it is also possible that phosphorylation of Thr 59 in intact cells is enhanced only when Ser 72 is phosphorylated. Several studies have also suggested that serine/threonine kinases have a preference for phosphorylating serine residues, whereas most serine/threonine phosphatases shows a striking bias towards dephosphorylating phosphothreonine residues [23] . This relative biasness may also account for the over-representation of serine residue phosphorylation in intact cells. Nevertheless, phosphorylation of either of the two sites appears to play a central role in stabilization of STEP. Ubiquitin is a small protein of 76 amino acids that marks a protein for degradation by the proteasome pathway [24, 25] . The formation of the polyubiquitin-protein complex is an ATP-dependent enzymatic process that requires the concerted efforts of E1, E2 and E3 ubiquitin ligases [26] . E3 ligases control the specificity of target protein selection and therefore are key to controlling target protein degradation. Although ubiquitination is involved in many cellular processes, only relatively recently has its involvement in neuronal function begun to be investigated [27] [28] [29] . Phosphorylation is the most common mechanism by which a stable protein can become a target for ubiquitination and subsequent degradation in neurons. For example, phosphorylation of p35 [a neuronalspecific activator of Cdk5 (cyclin-dependent kinase 5)] by Cdk5 kinase results in its degradation by an ubiquitin-mediated pathway [30] . Similarly, tyrosine phosphorylation of the NR2B-NMDA receptor in a Fyn kinase-dependent manner is also thought to result in ubiquitination and down-regulation of NMDA receptor function [31] . However, phosphorylation can also have an opposing effect of stabilizing a short-lived protein. In vertebrate neurons, NMDA receptor-dependent phosphorylation of c-Jun renders the transcription factor resistant to ubiquitin-mediated degradation and activates its ability to bind to DNA and initiate transcription [32] . A key finding of the present study is that endogenous phosphorylation of Thr 59 and Ser 72 residues within the KIS domain plays an important role in the stabilization of STEP.
Consistent with the requirement of multiple-site phosphorylation to maintain the stability of STEP, a single mutation of either of the two sites alone did not affect the stability of the protein. It is important to note that the requirement of multisite phosphorylation as the driving force for ubiquitination of a protein is well-established and is thought to increase the sensitivity of a protein for ubiquitin-mediated degradation [33] [34] [35] [36] . A previous study has also demonstrated a role for multi-site phosphorylation in the protection of a protein from ubiquitinmediated degradation; however, the underlying mechanism by which this occurs is not yet well understood [37] . One possible explanation for this phenomenon is that more than one kinase is involved in the phosphorylation of the two sites within the KIS domain in STEP and that dephosphorylation of a single site is not sufficient for ubiquitination and degradation. In this way, multi-site phosphorylation could serve to set a higher threshold for susceptibility to degradation.
Ubiquitination is increasingly recognized as a post-translational modification that, along with phosphorylation, is likely to be an important regulator of synaptic plasticity [29] . A previous study suggests that at glutamatergic synapses in the brain, activation of NMDA receptors can alter synaptic protein composition in an ubiquitin-proteasome-dependent manner [38] . In particular, PSD-95 (post-synaptic density-95), a scaffolding protein that regulates NMDA receptor-dependent synaptic plasticity through GRIA [glutamate receptor ionotropic AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid), also known as GluR] trafficking [39] [40] [41] has been shown to be a target for degradation by the ubiquitin-proteasome system. Ubiquitination of PSD-95 by ubiquitin ligase Mdm2, and its subsequent degradation, is regulated by the Ca 2 + -dependent phosphatase calcineurin [42] . STEP is part of the NMDA receptor complex [43] and NMDA receptor mediated activation of STEP is also regulated by calcineurin [9] . Since active STEP is more susceptible to degradation this leads us to speculate that calcineurin may also play a role in the degradation of active STEP, thereby limiting the duration of STEP signalling following its activation. This negative regulation may be one mechanism by which neurons may avert the pathophysiological consequences of overactivation of STEP.
Several lines of evidence suggest that dysfunction of the proteasomal degradation machinery plays an important role in the pathogenesis of neurodegenerative disorders [44] . Aberrant accumulation of ubiquitinated proteins due to a decline in proteasomal function has been reported in both AD (Alzheimer's disease) and Parkinson's disease [45] [46] [47] . Accumulating evidence from both animal models and human post-mortem studies suggests that a progressive increase in the generation of reactive oxygen and reactive nitrogen species may contribute to failure of the proteasomal system, leading to accumulation of ubiquitinated proteins involved in the pathology of these disorders [48, 49] . In this context, a recent study reported elevated levels of STEP 61 in the cortex of aged transgenic AD model mice (Tg2576) and in human AD brains [50] . This study also showed that in the AD mice model the elevated levels of STEP are ubiquitinated and associated with an increase in tyrosine phosphatase activity. Thus it appears that impairment of the proteasomal degradation machinery to remove STEP-ubiquitin conjugates may lead to the accumulation of active STEP 61 in AD. Consistent with this view the present study indicates that active STEP is more susceptible to degradation and that inhibition of the proteasomal machinery leads to accumulation of active STEP-ubiquitin conjugates. It is possible that such accumulation of active STEP may contribute, at least in part, to the pathophysiology of AD. Results from previous studies found that Aβ-induced activation of STEP leads to dephosphorylation of NR2B-NMDA receptor subunits and is responsible for endocytosis of functional NMDA receptors [13] . This raises the possibility that disruption of normal NMDA receptor trafficking as a result of Aβ-mediated accumulation of active STEP may contribute to the synaptic dysfunction as observed in AD.
Thus, taken together with the previous findings, the present study suggests that the KIS domain plays a role in maintaining the stability of STEP, and furthermore that dephosphorylation of the two SP/TP sites within the KIS domain is essential for the targeted degradation of active STEP by the ubiquitinproteasomal pathway. Such degradation of active STEP may be essential for the normal turnover of the protein. However, failure of the proteasomal degradation machinery and subsequent accumulation of active STEP-ubiquitin conjugate may contribute to the pathophysiology of a range of neurodegenerative disorders.
